A Phase 2 Study to Evaluate the Safety, Tolerability and Initial Efficacy of Pramipexole ER, Given With Aprepitant in Patients With Idiopathic Parkinson's Disease
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Pramipexole (Primary) ; Aprepitant
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Chase Therapeutics
- 11 Jul 2024 Planned End Date changed from 30 Dec 2024 to 30 Dec 2025.
- 11 Jul 2024 Planned primary completion date changed from 30 Dec 2024 to 30 Dec 2025.
- 05 Oct 2023 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.